Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
- PDF / 3,028,657 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 3 Downloads / 187 Views
ORIGINAL RESEARCH
Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19 Rashi Jain 1 & Somdutt Mujwar 1 Received: 10 June 2020 / Accepted: 30 July 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract The outbreak of severe acute respiratory syndrome coronavirus-2 is causing a serious disaster through coronavirus disease-19 (COVID-19) around the globe. A large segment of the population from every corner of the world is already infected with this dreadful pathogen with a high mortality rate. These numbers are increasing drastically causing a situation of a global pandemic. Although after the continuous scientific efforts, we are still not having any specific drug or vaccine for the SARS-CoV-2 pathogen to date and there is an urgent need to develop a newer therapy to counter the COVID-19 global pandemic. Thus, in the current study, a framework for computational drug repurposing is established, and based on their safety profile, metocurine was chosen as a safe and effective drug candidate for developing therapy against the viral Mpro enzyme of SARS-CoV-2 for the treatment of COVID-19. Keywords Drug repurposing . Drug repositioning . SARS-CoV-2 . COVID-19 . Corona . Antiviral
Introduction Coronaviruses are spherically enveloped particles accommodating single-stranded positive-sense RNA combined with a nucleoprotein in a capsid constituted of matrix protein. These are typified by the club-like spikes extruding from its surface. The virus contains uncommonly large RNA genome with an exclusive replication approach. It includes respiratory symptoms such as fever, cough, and inadequacy in breathing. The disease is coined as COVID-19 which is escalated by a novel Betacoronavirus. Coronavirus responsible for the epidemic is now termed as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which has 79% sequential similarity to SARSCoV, causing the outbreak in 2002-2003. SARS-CoV-2 was inclusive of Middle East Respiratory Syndrome (MERS) coronavirus. [1–3]. Coronavirus is transmitted from person-to-person when an infected individual person coughs or sneezes. This virus can * Somdutt Mujwar [email protected] Rashi Jain [email protected] 1
Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh 281406, India
also escalate via contaminated surfaces to hands and then to an individual. The transmission is usually via airborne droplets to the nasal mucosa, replicating narrowly in cells of ciliated epithelium leading to cell damage and inflammation [4, 5]. The virus enters the host cell, and uncoated genome transcribes and translates. The mRNAs assemble an onliest “nested set” allocating a common 3’ end [6]. New virions are developed through budding from host cell membranes. The coronavirus leads to acute and chronic respiratory, enteric, and CNS diseases in various species of animals, including humans [2]. These viruses plunder the respiratory tract via the nose. The symptoms of common cold along with nasal obstruc
Data Loading...
